(Q42625493)

4 November 2017

Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial (English)

1 reference

obsessive-compulsive disorder

4 November 2017

1 reference

1 reference

Dannon PN

1

1 reference

4 November 2017

Sasson Y

2

1 reference

4 November 2017

Hirschmann S

3

1 reference

4 November 2017

Iancu I

4

1 reference

4 November 2017

Grunhaus LJ

5

1 reference

4 November 2017

Zohar J

6

1 reference

4 November 2017

language of work or name

English

0 references

publication date

1 May 2000

1 reference

European Neuropsychopharmacology

4 November 2017

1 reference

4 November 2017

10

1 reference

4 November 2017

165-169

1 reference

4 November 2017

3

1 reference

Pindolol Induces a Rapid Improvement of Depressed Patients Treated With Serotonin Reuptake Inhibitors

4 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900065-1

7 January 2021

Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900065-1

7 January 2021

Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900065-1

7 January 2021

Pindolol does not act only on 5-HT1A receptors in augmenting antidepressant activity in the mouse forced swimming test

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900065-1

7 January 2021

Antagonist properties of (-)-pindolol and WAY 100635 at somatodendritic and postsynaptic 5-HT1A receptors in the rat brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900065-1

7 January 2021

Drug therapy. Pindolol: a new beta-adrenoceptor antagonist with partial agonist activity

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900065-1

7 January 2021

The epidemiology of obsessive-compulsive disorder in five US communities.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900065-1

7 January 2021

5-Hydroxytryptamine1A receptor responsivity in obsessive-compulsive disorder. Comparison of patients and controls

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900065-1

7 January 2021

Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900065-1

7 January 2021

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900065-1

7 January 2021

Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900065-1

7 January 2021

Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900065-1

7 January 2021

A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900065-1

7 January 2021

Evidence of the activity of lithium on 5-HT1B receptors in the mouse forced swimming test: comparison with carbamazepine and sodium valproate

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900065-1

7 January 2021

The role of 5-HT1A and 5-HT1B receptors in antidepressant drug actions in the mouse forced swimming test

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900065-1

7 January 2021

Effect of pindolol on the function of pre- and postsynaptic 5-HT1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900065-1

7 January 2021

How long should pindolol be associated with paroxetine to improve the antidepressant response?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900065-1

7 January 2021

Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900065-1

7 January 2021

Treatment of obsessive compulsive disorder: Algorithms for pharmacotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900065-1

7 January 2021

Obsessive compulsive disorder: Opportunities within and beyond the serotonergic domain

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900065-1

7 January 2021

10.1016/S0924-977X(00)00065-1

Identifiers

DOI

1 reference

4 November 2017

1 reference